Helminth Assay Network
A proposed network to connect helminth drug and target hypotheses with real parasite assays.
The assay bottleneck
For many helminths, the hardest step is not imagining a target or finding a molecule. It is testing the idea in the right living parasite system. Many worms have complex life cycles involving humans, livestock, snails, insects, mites, fish, rodents or environmental stages. Some adult parasites live in anatomical niches that are difficult or ethically impossible to reproduce in the laboratory.
The field therefore needs a practical assay map: which species can be cultured, which life stages can be tested, which surrogate species are accepted, and where there are still major gaps. A good assay map should make weak points visible rather than smoothing them away.
Model systems and assay routes
Assay-readiness key: Green suitable same-species or very close species phenotypic screening model available; Amber useful model exists, but it is partial, surrogate, low-throughput or not the main human species; Red no credible scalable drug-discovery model identified.
| Parasite / disease area | Laboratory system or surrogate | What can be measured | Evidence and URLs |
|---|---|---|---|
| Adult cestode models GreenHymenolepis microstoma, H. diminuta | Mouse/rat-hosted Hymenolepis models with adult worms accessible for drug testing. | Adult tapeworm survival, scolex attachment, segmentation, egg output, cestocidal activity and adult-cestode biology. | H. microstoma model; tribendimidine in H. microstoma. |
| Alveolar echinococcosis GreenEchinococcus multilocularis | Same-species metacestode vesicles, primary cells and germinative-cell systems maintained in vitro; rodents for in vivo validation. | Vesicle growth, germinative-cell survival, stem-cell pathway inhibition, parasite viability, metabolism and target validation. | Brehm lab; germinative-cell paper; metacestode culture metabolomics; EmER1 / afatinib paper. |
| Ascariasis AmberAscaris lumbricoides, A. suum | A. suum from pigs supports ex vivo neuromuscular, pharyngeal and larval electrophysiology assays; it is useful but not a simple same-species human HTS model. | Motility, neuromuscular pharmacology, egg development, larval migration biology, receptor/channel target work and comparative anthelmintic benchmarking across intestinal nematode laboratory models. | A. suum body-muscle electrophysiology; A. suum pharyngeal preparation; microfluidic hookworm/Ascaris larvae platform; laboratory-model benchmarking. |
| Cystic echinococcosis AmberEchinococcus granulosus sensu lato | Protoscolex and metacestode culture systems; dog/sheep life-cycle biology and livestock intervention models. | Protoscolex viability, cyst development, metacestode growth, drug sensitivity and One Health intervention modelling. | E. granulosus in vitro culture comparison; EG95 sheep vaccine trials; Morocco field evaluation. |
| Cysticercosis / taeniasis AmberTaenia solium | Pig infection and intervention models; oncosphere/cysticercus-stage assays where available. Hymenolepis rodent tapeworms are adult-cestode surrogates, not direct T. solium HTS models. | Porcine cyst burden, transmission-blocking vaccination, oxfendazole response, adult tapeworm pharmacology and cestode development. | TSOL18 vaccine development review; Hymenolepis model description; Hymenolepis drug model. |
| Food-borne liver flukes AmberClonorchis sinensis, Opisthorchis viverrini | C. sinensis metacercariae/newly excysted juvenile assays and rat models; O. viverrini hamster infection and cancer-biology models. | Metacercarial and juvenile killing, adult worm burden in rodents, biliary pathology, carcinogenesis-linked biology and praziquantel/repurposed-drug sensitivity. | Clonorchis HTS / rat model; Clonorchis rat chemotherapy model; Opisthorchis hamster model. |
| Guinea worm disease RedDracunculus medinensis | — | No credible scalable drug-discovery assay identified; eradication work is surveillance, containment, water safety and animal-reservoir control rather than drug screening. | Carter Center Guinea worm programme. |
| Human hookworm AmberNecator americanus, Ancylostoma duodenale | No routine same-species HTS platform equivalent to A. ceylanicum; discovery commonly uses A. ceylanicum, controlled human infection endpoints and larval assays. | Adult hookworm activity by surrogate, larval motility, anaemia-relevant endpoints, controlled human infection, species validation and comparative commercial-anthelmintic benchmarking. | A. ceylanicum discovery pipeline; hookworm / Strongyloides larval motility assay; laboratory-model benchmarking. |
| Liver fluke / fasciolosis GreenFasciola hepatica | Same-species newly excysted juvenile and adult F. hepatica in vitro culture; juvenile growth and motility assays; adult culture workflows. | Juvenile growth, motility, survival, tegument and gut damage, RNAi/functional genomics, triclabendazole sensitivity and resistance-associated phenotypes. | juvenile in vitro growth paper; adult culture workflow; miracidial motility assay. |
| Loiasis RedLoa loa | — | No credible scalable same-species drug-discovery model identified; work depends on field-derived material, safety pharmacology and related filarial models. | WHO co-endemic onchocerciasis context. |
| Lung flukes RedParagonimus spp. | — | No credible scalable drug-discovery assay identified; current work is mainly clinical, diagnostic, epidemiological and life-cycle biology. | CDC paragonimiasis context. |
| Lymphatic filariasis field species AmberWuchereria bancrofti, B. timori | Discovery usually depends on B. malayi as a close filarial model, followed by programme and species-relevant validation. | Anti-Wolbachia response, microfilarial clearance, adult-worm effects inferred through programme endpoints and validation studies. | FR3 reagent resource; anti-Wolbachia review. |
| Lymphatic filariasis model GreenBrugia malayi | B. malayi in jirds/gerbils and mosquitoes; adult and microfilaria in vitro culture; automated motility tracking. | Adult motility, microfilarial movement, Wolbachia depletion, microfilariae release, macrofilaricidal activity, phenotypic tracking and structured screening-cascade progression. | B. malayi jird model; BrugiaTracker assay; FR3 reagent resource; phenotypic screening cascade. |
| Onchocerciasis AmberOnchocerca volvulus | Onchocerca ochengi cattle material where available; Litomosoides sigmodontis and Acanthocheilonema viteae animal models for filarial biology; O. volvulus in vitro culture systems where available; adult O. volvulus access remains limited. | Microfilarial response, Wolbachia biology, macrofilaricidal activity, nodular adult-worm endpoints, immunology, surrogate filarial drug response, human-parasite-relevant culture conditions and preclinical bridging from in vitro activity to in vivo efficacy. | Litomosoides model page; L. sigmodontis method paper; Bonn filariasis groups; O. volvulus in vitro culture system; filarial animal models; phenotypic screening cascade. |
| Schistosomiasis GreenSchistosoma mansoni | Same-species schistosomula and adult-worm in vitro assays; full life cycle in Biomphalaria snails and rodents at specialist centres. | Schistosomula viability, adult motility, tegument damage, pairing, egg output, juvenile/adult drug sensitivity and resistance-marker work. | schistosome life-cycle methods; Hoffmann lab; Caffrey lab. |
| Strongyloidiasis AmberStrongyloides stercoralis | Strongyloides ratti and S. venezuelensis rodent systems; free-living and parasitic larval-stage assays. | Larval development, motility, survival, drug sensitivity, autoinfection-relevant biology and transgenesis-adjacent methods. | Strongyloides model methods; larval motility assay; S. ratti drug model. |
| Toxocariasis and larva migrans AmberToxocara canis, T. cati, zoonotic hookworms | Egg/larval systems, mouse migration models and dog/cat veterinary parasite systems; not a mature HTS discovery lane. | Larval migration, tissue persistence, motility, egg development and veterinary-control endpoints. | CDC Toxocara biology; Toxocara mouse model review. |
| Trichinellosis AmberTrichinella spiralis | Mouse infection models and muscle-larva systems support biology and drug/vaccine evaluation, but not a routine same-species HTS pipeline. | Adult intestinal stage, muscle larvae, burden reduction, immune pathology and candidate readouts. | CDC life-cycle context; Trichinella mouse model example. |
| Urogenital and Asian schistosomiasis AmberS. haematobium, S. japonicum | Species-specific systems exist in some laboratories, but routine discovery often leans on S. mansoni assays and targeted validation in the species of interest. | Species validation, praziquantel response, resistance surveillance, adult-worm biology and field-linked efficacy questions. | RESIST; WHO efficacy monitoring guidance. |
| Veterinary gastrointestinal nematodes GreenHaemonchus contortus and related strongylids | Same-species H. contortus larval HTS, egg hatch/larval development assays, ex vivo adult motility assays and livestock infection/FECRT systems. C. elegans is only a distant comparator, not a substitute. | Egg hatch, larval development, automated larval motility, adult motility/feeding, faecal egg-count reduction, resistance phenotypes and flock/herd-level control. | H. contortus larval HTS assay; comparative in vitro assays; adult-stage motility assay; larval development assay; COMBAR. |
| Whipworm AmberTrichuris trichiura modelled by T. muris | T. muris in mice; adult ex vivo motility and L1 motility assays. Useful, but not same-species T. trichiura HTS. | Adult motility, larval motility, mouse worm burden, gut immune response, epithelial interaction, metabolism-informed prioritisation and species-aware benchmarking of anthelmintic readouts. | T. muris L1 assay; T. muris adult motility screen; 409-drug whipworm screen; laboratory-model benchmarking. |
| Zoonotic hookworm model GreenAncylostoma ceylanicum | Same-species larval and adult hookworm screening pipeline using A. ceylanicum; golden-hamster infection model. | Larval motility/development, adult survival, egg output, worm burden, large compound-library screening and intestinal-nematode assay benchmarking. | 30,000-compound hookworm screen; broad-spectrum STH screen; A. ceylanicum egg HTS; laboratory-model benchmarking. |
Helminthix role
The Helminth Assay Network would help match target or molecule hypotheses with the assay system most likely to produce a meaningful answer. The goal is not to centralise all parasite work, but to make it easier for researchers, AI teams and funders to find the right experimental partners.